Cullinan Therapeutics (CGEM) closed at $10.28 on November 13, 2026, up 0.9% from the previous close, on volume of 1,339,490 shares (30-day average 838,308).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 16, 2026 | Calendar Put Spread | 16-Oct : 20-Nov-26 15 P | 2,000 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Thu, 12-Nov 4:30 PM ET)
Guggenheim Sticks to Their Buy Rating for Cullinan Management (CGEM)
TipRanks (Thu, 12-Nov 7:45 AM ET)
TipRanks (Wed, 11-Nov 1:00 AM ET)
Cullinan Buy Rating Reaffirmed at $36 as CLN-978 and CLN-049 Clinical Catalysts Approach
TipRanks (Tue, 10-Nov 5:25 PM ET)
Cullinan Therapeutics reports Q3 results
Seeking Alpha News (Tue, 10-Nov 9:41 AM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Tue, 10-Nov 8:40 AM ET)
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Cullinan Management (CGEM) Receives a Rating Update from a Top Analyst
TipRanks (Mon, 9-Nov 11:15 AM ET)
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 9-Nov 10:00 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Wave Life Sciences (WVE), Ascendis Pharma (ASND)
TipRanks (Mon, 9-Nov 8:50 AM ET)
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Cullinan Therapeutics trades on the NASDAQ stock market under the symbol CGEM.
As of November 13, 2026, CGEM stock price climbed to $10.28 with 1,339,490 million shares trading.
CGEM has a beta of 1.65, meaning it tends to be more sensitive to market movements. CGEM has a correlation of 0.06 to the broad based SPY ETF.
CGEM has a market cap of $667.39 million. This is considered a Small Cap stock.
Last quarter Cullinan Therapeutics reported $0 in Revenue and -$.74 earnings per share. This fell short of revenue expectation by $-402,000 and exceeded earnings estimates by $.09.
In the last 3 years, CGEM traded as high as $30.19 and as low as $5.68.
The top ETF exchange traded funds that CGEM belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWN.
CGEM has outperformed the market in the last year with a return of +24.3%, while the SPY ETF gained +13.4%. However, in the most recent history, CGEM shares have underperformed the stock market with its stock returning -47.7% in the last 3 month period and -31.6% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
CGEM support price is $9.61 and resistance is $10.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGEM shares will trade within this expected range on the day.
